Lineage Cell Therapeutics Inc (NYSE MKT:LCTX) — Market Cap & Net Worth
Market Cap & Net Worth: Lineage Cell Therapeutics Inc (LCTX)
Lineage Cell Therapeutics Inc (NYSE MKT:LCTX) has a market capitalization of $299.43 Million ($299.43 Million) as of August 1, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #14619 globally and #3474 in its home market, demonstrating a -0.76% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lineage Cell Therapeutics Inc's stock price $1.30 by its total outstanding shares 230327537 (230.33 Million). See LCTX capex reinvestment rate to understand how much of operating cash flow is reinvested back into capital assets.
Lineage Cell Therapeutics Inc Market Cap History: 2015 to 2026
Lineage Cell Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows change from $810.36 Million to $299.43 Million (-8.82% CAGR).
Lineage Cell Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lineage Cell Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
12.18x
Lineage Cell Therapeutics Inc's market cap is 12.18 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $810.36 Million | $2.53 Million | -$46.99 Million | 319.80x | N/A |
| 2016 | $772.38 Million | $2.25 Million | $33.57 Million | 342.98x | 23.01x |
| 2017 | $460.01 Million | $1.79 Million | -$19.98 Million | 256.70x | N/A |
| 2018 | $210.29 Million | $1.42 Million | -$45.99 Million | 148.51x | N/A |
| 2019 | $204.99 Million | $1.48 Million | -$11.71 Million | 138.70x | N/A |
| 2020 | $405.38 Million | $773.00K | -$20.65 Million | 524.42x | N/A |
| 2021 | $564.30 Million | $3.90 Million | -$43.02 Million | 144.84x | N/A |
| 2022 | $269.48 Million | $14.70 Million | -$26.27 Million | 18.33x | N/A |
| 2023 | $251.06 Million | $8.95 Million | -$21.49 Million | 28.07x | N/A |
| 2024 | $115.74 Million | $9.50 Million | -$18.61 Million | 12.18x | N/A |
Competitor Companies of LCTX by Market Capitalization
Companies near Lineage Cell Therapeutics Inc in the global market cap rankings as of August 1, 2026.
Key companies related to Lineage Cell Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #537 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- Samsung Biologics Co Ltd (KO:207940): Ranked #556 globally with a market cap of $47.90 Billion USD ( ₩70.69 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $481.70 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $738.34 |
| #537 | Argen-X | BR:ARGX | $49.55 Billion | €746.60 |
| #556 | Samsung Biologics Co Ltd | KO:207940 | $47.90 Billion | ₩1527000.00 |
Lineage Cell Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Lineage Cell Therapeutics Inc's market cap moved from $810.36 Million to $ 299.43 Million, with a yearly change of -8.82%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $299.43 Million | -22.16% |
| 2025 | $384.65 Million | +232.34% |
| 2024 | $115.74 Million | -53.90% |
| 2023 | $251.06 Million | -6.84% |
| 2022 | $269.48 Million | -52.24% |
| 2021 | $564.30 Million | +39.20% |
| 2020 | $405.38 Million | +97.75% |
| 2019 | $204.99 Million | -2.52% |
| 2018 | $210.29 Million | -54.29% |
| 2017 | $460.01 Million | -40.44% |
| 2016 | $772.38 Million | -4.69% |
| 2015 | $810.36 Million | -- |
End of Day Market Cap According to Different Sources
On Jul 31st, 2026 the market cap of Lineage Cell Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $299.43 Million USD |
| MoneyControl | $299.43 Million USD |
| MarketWatch | $299.43 Million USD |
| marketcap.company | $299.43 Million USD |
| Reuters | $299.43 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic… Read more